CNS Pharmaceuticals (NASDAQ:CNSP) Raised to Buy at Maxim Group

CNS Pharmaceuticals (NASDAQ:CNSP) was upgraded by Maxim Group from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a $0.50 price target on the stock. Maxim Group’s price objective indicates a potential upside of 252.11% from the stock’s previous close.

CNS Pharmaceuticals Price Performance

Shares of CNSP opened at $0.14 on Tuesday. CNS Pharmaceuticals has a 12-month low of $0.10 and a 12-month high of $137.50. The business has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $7.62. The stock has a market cap of $204,906.00, a PE ratio of 0.00 and a beta of 2.58.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On CNS Pharmaceuticals

A hedge fund recently bought a new stake in CNS Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 122,000 shares of the company’s stock, valued at approximately $155,000. Armistice Capital LLC owned 1.96% of CNS Pharmaceuticals at the end of the most recent quarter. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.